Ayuvant

1 known investors

Ayuvant is developing an RNA-nanoparticle immunotherapy designed to direct the immune system to recognize and attack cancer cells. The platform targets patients who do not respond to existing immune checkpoint inhibitors and has shown antitumor activity in checkpoint-inhibitor-resistant models.